Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Authors
Keywords
-
Journal
CIRCULATION
Volume 143, Issue 4, Pages 337-349
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-11-12
DOI
10.1161/circulationaha.120.051824
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
- (2020) Milton Packer DIABETES CARE
- Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
- (2020) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Impaired fasting glucose and development of chronic kidney disease in non-diabetic population: a Mendelian randomization study
- (2020) Hyoungnae Kim et al. BMJ Open Diabetes Research & Care
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events
- (2019) Naveen Rathi et al. AMERICAN JOURNAL OF HYPERTENSION
- Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
- (2019) Milton Packer et al. EUROPEAN JOURNAL OF HEART FAILURE
- Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients
- (2019) Chen Die Yang et al. Cardiovascular Diabetology
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE
- (2016) Søren L. Kristensen et al. Circulation-Heart Failure
- Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices
- (2010) Nir Uriel et al. EUROPEAN JOURNAL OF HEART FAILURE
- Insulin-Resistant Cardiomyopathy
- (2008) Ronald M. Witteles et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More